226 related articles for article (PubMed ID: 35804865)
1. PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy
Wang Y; Rousset X; Prunier C; Garcia P; Dosda E; Leplus E; Viallet J
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804865
[TBL] [Abstract][Full Text] [Related]
2. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
3. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
[TBL] [Abstract][Full Text] [Related]
4. Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.
Mabbitt J; Holyer ID; Roper JA; Nilsson UJ; Zetterberg FR; Vuong L; Mackinnon AC; Pedersen A; Slack RJ
Front Immunol; 2023; 14():1250559. PubMed ID: 37701441
[TBL] [Abstract][Full Text] [Related]
5. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Gibbons Johnson RM; Dong H
Front Immunol; 2017; 8():961. PubMed ID: 28848559
[TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.
Khunger M; Hernandez AV; Pasupuleti V; Rakshit S; Pennell NA; Stevenson J; Mukhopadhyay S; Schalper K; Velcheti V
JCO Precis Oncol; 2017 Nov; 1():1-15. PubMed ID: 35172490
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
11. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Lantuejoul S; Damotte D; Hofman V; Adam J
J Thorac Dis; 2019 Jan; 11(Suppl 1):S89-S101. PubMed ID: 30775032
[TBL] [Abstract][Full Text] [Related]
13. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
[No Abstract] [Full Text] [Related]
14. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
16. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
17. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of
Baraibar I; Roman M; Rodríguez-Remírez M; López I; Vilalta A; Guruceaga E; Ecay M; Collantes M; Lozano T; Alignani D; Puyalto A; Oliver A; Ortiz-Espinosa S; Moreno H; Torregrosa M; Rolfo C; Caglevic C; García-Ros D; Villalba-Esparza M; De Andrea C; Vicent S; Pío R; Lasarte JJ; Calvo A; Ajona D; Gil-Bazo I
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33126649
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
19. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]